Citations

Clear

2303 citation(s) found for "Yu, Edward".

Self-Motion Perception Influences Postural Sway More than Environmental Motion Perception
Critelli, Kyle, Carpenter, Mark G. , Anson, Eric R , Chen, Edward , Staab, Jeffrey P. , Crane, Benjamin Thomas

Mayo Clinic

No container title available | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.02.651511 | PMID 40655001 Get It

Abstract Motion of the visual field can alter postural sway and cause illusions of self-motion. The relative perceptual sensitivity of self-motion versus visual field motion induced by virtual reality (VR) stimulation and whether observable sway differs based on perceptual task is unknown. Methods to quantify sway perception while concurrently measuring sway do not exist. We measured head sway and motion perception (self or world) in healthy adults who stood with feet together wearing a VR headset while experiencing adaptive staircases of virtual sinusoidal pitch rotation about the ankle axis. In separate conditions of randomly ordered blocks, subjects were asked to indicate (yes/no) if the room moved (regardless of perceived postural sway) or if their postural sway increased (regardless of perceived room motion). Head sway area was measured by tracking movement of the VR headset. Yes/No responses were fit with psychometric curves to determine points of subjective equality (PSEs) for room motion and postural sway. PSEs were compared between conditions. Effects of motion perception (binary responses) on head sway area before, during, and after visual stimulation were examined. The mean PSE for room motion (0.42 degrees) was significantly lower than for postural sway (2.02 degrees) [t(1,18) = 4.4714, p = 0.00029]. Head sway area was significantly larger during (z = 11.53, p < 0.001) and after (z = 5.09, p < 0.001) visual stimulation only when participants perceived increased postural sway. Nearly 5-fold greater amplitudes of oscillating VR visual stimuli were required to induce perceptions of altered self-versus visual field motion. Observed head sway during visual motion was only linked to perceptual responses when participants focused internally on self-motion, not externally on room motion.
Delphi Panel for the Development of Diagnostic Criteria for Metastatic Cutaneous Crohn Disease
Ebriani, Joseph, Santiago-Soltero, Karla , Anshelevich, Ellen, Shields, Bridget E. , Charrow, Alexandra , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Burgin, Susan , Cices, Ahuva , Coromilas, Alexandra, Rosenbach, Misha , Shaw, Katharina S. , Watson, Alice J., Ebriani, Joseph , Dalal, Rahul S. , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Agrawal, Manasi , Alavi, Afsáneh , Cowen, Edward W , Goldfarb, Noah , Hsiao, Jennifer L. , McGee, Jean S. , Ortega‐Loayza, Alex G. , Porter, Martina Lee , Wanat, Karolyn A. , Wong, Serre-Yu

Mayo Clinic

JAMA Dermatology | May 7, 2025 | Volume: 161 | Issue: 6 | Pages: 642

10.1001/jamadermatol.2025.1115 | PMID 40332924 Get It

ImportanceMetastatic cutaneous Crohn disease (MCD) is a rare condition for which there are currently no published diagnostic criteria. Formal MCD diagnostic criteria will expand clinical care and research by enabling future diagnostic code validation, crystallizing a more uniform disease entity for the purposes of translational research, and allowing the development of more formalized outcome measures aimed at treatment response.ObjectiveTo define a set of criteria for the diagnosis of MCD.Evidence ReviewIn this consensus statement, a panel of experts on MCD and related conditions was assembled. Their opinions were gathered regarding the clinical and histologic findings that are sufficient, necessary, and highly suggestive of MCD through serial survey. Subsequent surveys were continued until consensus was achieved. Sufficient was defined as a feature that, if noted, would enable diagnosis of MCD without any other signs, symptoms, or testing. Necessary was defined as a feature that must be present to establish a diagnosis of MCD. Highly suggestive referred to any other features that were indicative of MCD but did not qualify as sufficient or necessary to diagnose MCD.FindingsOf 24 experts invited, 19 agreed to participate, with a 79% to 100% response rate across 5 rounds conducted. Five patients were also invited to participate, but none opted to participate, citing lack of clinical expertise and time concerns. The experts were all from the US; 5 (26%) have practiced medicine for 0 to 5 years, 5 (26%) practiced for 6 to 10 years, 6 (32%) practiced for 11 to 15 years, and 3 (16%) practiced for more than 20 years. A total of 18 experts (95%) worked in an academic practice setting. There was consensus agreement that MCD could present as oral disease, genital disease, or, rarely, in another location. Consensus was achieved on 2 major and 5 minor criteria for genital/other subtypes of MCD and 5 minor criteria for oral MCD. There was consensus that, while there are some pathological findings that are highly suggestive of MCD, histologic criteria are not necessary for diagnosis.Conclusions and RelevanceA panel of experts reached consensus on the diagnostic criteria for MCD described in this study. These criteria include major and minor clinical criteria, along with histopathological criteria for the diagnosis of genital and oral MCD. This consensus is a crucial step in the diagnosis of and future treatment development for MCD, a rare and clinically understudied condition.
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
D’Haens, Geert , Panaccione, Remo , Matsuoka, Katsuyoshi , Loftus, Edward V. , Kobayashi, Taku , Elsharkawi, Walid, Miceli, Rosa, Ahmed, Samia A. , Napoli, Andrew, Vaile, John, Dornic, Quentin, Patel, Aditya , Danese, Silvio , Panaccione, Remo , Kobayashi, Taku , Schreiber, Stefan , Loftus, Edward V , Danese, Silvio , Rubin, David T. , Peyrin‐Biroulet, Laurent , Luo, Yi , Matsuoka, K

Mayo Clinic

Journal of Crohn's and Colitis | May 3, 2025 | Volume: 19 | Issue: 6 | Pages: No page available

10.1093/ecco-jcc/jjaf080 | PMID 40355364 Get It

Abstract Background and Aims Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis of inflammatory bowel disease. Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 inhibitor currently approved for the treatment of adults with moderate to severe plaque psoriasis. Methods Here we describe 3 randomized, double-blind, placebo-controlled phase 2 studies of deucravacitinib in patients with moderately to severely active Crohn’s disease (LATTICE-CD [NCT03599622]) or ulcerative colitis (LATTICE-UC [NCT03934216] and IM011-127 [NCT04613518]). Patients were randomized to receive placebo or twice-daily deucravacitinib 3 or 6 mg (LATTICE-CD), 6 mg (LATTICE-UC), or 12 mg (IM011-127) for 12 weeks. Coprimary endpoints for LATTICE-CD were clinical remission and endoscopic response at week 12. The primary endpoint was clinical remission (per modified Mayo score) at week 12 for LATTICE-UC and clinical response (per modified Mayo score) at week 12 for IM011-127. Results A total of 239 (LATTICE-CD), 131 (LATTICE-UC), and 38 (IM011-127) patients were randomized. The primary endpoints were not met for all 3 studies, which resulted in early study termination for LATTICE-CD and IM011-127. High efficacy rates were observed in placebo groups throughout the studies. In all studies, the safety profile of deucravacitinib was consistent with the known safety profile observed in patients with psoriasis, and no new safety signals were observed. Conclusions Deucravacitinib at multiple doses did not demonstrate significant clinical benefit vs placebo in moderately to severely active Crohn’s disease or ulcerative colitis. Deucravacitinib was safe and well tolerated.
The Future of Robotics in Plastic and Reconstructive Surgery
Payne, Camryn, Martinez, Casey , Spronsen, Nicole Van , Shrout, Max A., Morris, Bryn E., Casey, William J., Rhee, Daniel H. , Reece, Edward, Yi, Johnny , Rebecca, Alanna M. , Payne, Cynthia S. , Van Spronsen, Nicole, Shrout, Max, Casey, William, Rhee, Daniel, Rebecca, Alanna, Payne, Camryn S , Payne, Camryn, Jungbauer, Walter N

Mayo Clinic

Annals of Plastic Surgery | May 1, 2025 | Volume: 94 | Issue: 5S | Pages: S421-S424

10.1097/sap.0000000000004278 | PMID 40310003 Get It

Abstract Robots have been used effectively in plastic and reconstructive surgery (PRS) for reconstruction. The utilization of robotics in all surgical specialties is expanding with the goal of offering the most appropriate patient-centered care possible, especially in complex multidisciplinary cases. Despite the safety, efficiency, and reproducibility of robotics in PRS, there is a paucity of required and formalized training in PRS residency programs. The ACGME and industry published guidelines were investigated. Robotic surgery case logs of Mayo Clinic Arizona General Surgery residents were analyzed with attention to equivalency certification (EQ). Over the past 5 years, the equivalency certification from Intuitive (Sunnyvale, CA) was obtained by 30% of all general surgery residents at our institution (range, 0–100). The case numbers to obtain the equivalence certification are industry recommendations, and proficiency is determined by the program director. The ACGME does not mandate robotics training in general surgery residency. According to the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), trainees must complete 20 console cases and 10 bedside cases to become industry certified. With respect to training and advancing the field, PRS residents could successfully obtain certification in their residency programs. The minimum case requirement recommended by SAGES is not burdensome and can ensure robotic privileges in PRS practice immediately following graduation. By improving the training for minimally invasive robotic surgery in plastic surgery, patients and healthcare systems benefit from improved quality of life outcomes and decreased postoperative length of stay, which results in less strain on our entire medical system.
Rethinking the Diagnosis and Management of Antibody‐Mediated Rejection in Multidisciplinary Transplant Meetings: A Global Survey and Banff Working Group Recommendations
Sapir‐Pichhadze, Ruth , Cornell, Lynn D. , Dadhania, Darshana M. , Vries, Aiko P. J. de , Schinstock, Carrie A. , Carroll, Robert , Abdelrehim, Ahmad, Gan, Geliang, Deng, Yanhong , Alasfar, Sami , Bagnasco, Serena M. , Groningen, Marian C. Clahsen‐van , Kung, Vanderlene L. , Lower, Fritz, Seija, Mariana , Kraus, Edward S., Bow, Laurine M., Group, the Banff Antibody‐Mediated Injury Working, Dadhania, Darshana M , Schinstock, Carrie , Carroll, Robert P , Clahsen-van Groningen, Marian C , Cornell, Lynn , de Vries, Aiko P J , Askar, Medhat , Cooper, Matthew , Cozzi, Emanuele , Diekmann, Fritz , Gan, Geliang, Batal, Ibrahim , Budde, Klemens , Naesens, Maarten , Group, the Banff Antibody‐Mediated Injury Working

Mayo Clinic

Clinical Transplantation | April 28, 2025 | Volume: 39 | Issue: 5 | Pages: No page available

10.1111/ctr.70167 | PMID 40294134 Get It

ABSTRACTIntroductionThe diagnosis of antibody‐mediated rejection (AMR) requires input from several transplant professionals. Bringing clinical and laboratory experts together may help standardize care. Yet, little is known about current global practices of multidisciplinary meetings for AMR management.MethodsThe Banff Antibody‐Mediated Injury Working Group approached professional societies worldwide to distribute a survey on the availability, content, participants, perceived value, and barriers to the implementation of multidisciplinary meetings.ResultsFour hundred two transplant professionals from six continents caring for kidney (90.55%), liver (21.14%), pancreas (20.65%), heart (15.17%), and lung (14.18%) transplant recipients participated in the survey, and 302 (75.12%) reported attending multidisciplinary meetings. Multidisciplinary meetings were more prevalent in academic centers, in high‐ versus low‐to‐middle‐income regions (81.03% and 65.99%, respectively; p < 0.001), and in mid‐to‐large size transplant programs compared to smaller programs. Perceived value included continued professional development (97.68%) and trainee education (95.70%). AMR was reported to be discussed at these meetings by 217 respondents with case presentations reviewing patient characteristics, histology, and HLA antibody data. A third of the respondents reviewed non‐HLA/pathogenic autoantibodies and/or molecular diagnostics, with the latter being more frequently applied in high‐ versus low‐to‐middle‐income regions (46.71% and 12.31%, respectively; p < 0.001). AMR case presentations allowed diagnosis revision, actionable management plans and were perceived as improving care. The primary barrier to the implementation of multidisciplinary meetings (63.27%) was the unavailability of transplant professionals (e.g., transplant immunologists).ConclusionFacilitating multidisciplinary meetings through the remote participation of pertinent experts and incentivizing participation through remuneration, protected time, or continued medical education may help standardize AMR diagnosis and harmonize its management.
Cardiac myosin inhibitors for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials
Hasana, Uswa, Korpal, Mayank, Haider, Faseeh , Umer, Mohammad , Lwin, Nang Phyu Thant, Iqbal, Sohaba, Kumar, Rajanikant , Ahsan, Maria, Hassan, Ebaad, Ullah, Waheed , Khalid, Saif, Gupta, Akhil , Alsubari, Asma’a Munasar Ali, Ahmad, Adeel , Lwin, Nang Phyu Thant, Iqbal, Sohaba, Ullah, Waheed, Khalid, Saif, Ehsan, Muhammad

Mayo Clinic

Annals of Medicine & Surgery | April 28, 2025 | Volume: 87 | Issue: 6 | Pages: 3810-3818

10.1097/ms9.0000000000003326 | PMID 40486562 Get It

Background/objective: HCM is a structural disorder of the myocardium that leads to sudden cardiac death in young adults. We synthesized an updated understanding of the role of Cardiac Myosin Inhibitors (CMIs) in HCM by pooling data from RCTs. Methods: We identified six published RCTs, involving 826 participants. Data were extracted pertaining to study characteristics; primary outcomes of interest–(1) change from baseline in resting left ventricular outflow tract (LVOT) peak gradient, (2) change from baseline in Valsalva LVOT peak gradient, and (3) improvement of ≥1 NYHA class–and secondary outcomes. These were pooled using Review Manager 5.4, employing a random-effects model, and reported as odds ratios (ORs) or mean differences (MDs). Results: We found statistically significant between-group difference favoring CMIs in change from baseline in LVOT peak gradient: at rest (MD −39.33; −53.01 to −25.64), post-Valsalva (MD −48.99; −53.96 to −44.03), and post-exercise (MD −37.11; −44.34 to −29.87); ≥1 NYHA class improvement (OR 4.10; 2.79–6.02), change from baseline in peak oxygen uptake (MD −37.11; −44.34 to −29.87), LVOT gradient ≤30 mm hg (RR 14.89; 7.47–29.67), participants eligible for septal reduction therapy (RR 0.26; 0.18–0.36), and change from baseline in KCCQ-CSS score (MD 8.54; 5.36–11.71). Subgrouping by intervention type (mavacamten vs. aficamten) revealed non-significant results for all primary outcomes. Conclusions: CMIs can contribute to improving key efficacy outcomes for patients with HCM while reducing incidence of SRT.
68. The Use of Spino-plastic Surgery in Patients With Complex Spinal Reconstructive Needs: An Initial Cohort And Associated Outcomes
Reece, Edward M., Buchanan, D., Unadkat, Krishna , Vernik, Daniel M. , Jeger, Jonathan L. , Spronsen, Nicole R. Van, Meyer, Jenna H., Kalani, Maziyar A. , Unadkat, Krishna D , Jungbauer, Walter N , Buchanan, Dylon C., Jeger, Jonathan L , Spronsen, Nicole Van

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 25, 2025 | Volume: 13 | Issue: S1 | Pages: 46-47

10.1097/01.gox.0001112224.42767.e4 Get It

Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia
Liu, Xulin , Cortez, Kasey, Poos, Jackie M. , Illán‐Gala, Ignacio , Heuer, Hilary W. , Forsberg, Leah K. , Casaletto, Kaitlin B. , Memel, Molly , Barmada, Sami J. , Clark, David , Darby, Ryan, Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Kantarci, Kejal, Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Roberson, Erik D. , Rogalskı, Emily , Bouzigues, Arabella , Russell, Lucy L. , Foster, Phoebe H. , Ferry‐Bolder, Eve , Masellis, Mario, Jiskoot, Lize C. , Laforce, Robert, Graff, Caroline , Galimberti, Daniela, Vandenberghe, Rik, Santana, Isabel, Xiong, Chengjie , Sorbi, Sandro , Otto, Markus , Pasquier, Florence, Ducharme, Simon , Butler, Christopher , Ber, Isabelle Le, Synofzik, Matthis , Moreno, Fermín , Boxer, Adam L. , Rosen, Howie, Rohrer, Jonathan D., Kantarci, Kejal , Galimberti, Daniela , Bocchetta, Martina , Moreno, Fermín , Boeve, Brad F, Roberson, Erik , Kantarci, Kejal , Pascual, Belen , Synofzik, Matthis , Xiong, Chengjie , Domoto-Reilly, Kimiko , Barmada, Sami , Otto, Markus , Illán-Gala, Ignacio , Galimberti, Daniela , Russell, Lucy L , Bocchetta, Martina , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Boer, Sterre C.M. de , Appleby, Brian S. , Bozoki, Andrea C , Cobigo, Yann , Dickerson, Bradford Clark , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Irwin, David J. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Bayram, Ece , Swieten, John C. van , Seelaar, Harro , Sánchez‐Valle, Raquel , Laforce, Robert , Vandenberghe, Rik , Mendonça, Alexandre de , Tiraboschi, Pietro , Santana, Isabel , Gerhard, Alexander , Pasquier, Florence , Ber, Isabelle Le , Finger, Elizabeth C. , Rowe, James B. , Borroni, Barbara , Boeve, Bradley F. , Pijnenburg, Yolande A.L. , Rohrer, Jonathan D. , Tartaglia, Maria Carmela

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14608 | PMID 40277074 Get It

AbstractINTRODUCTIONHigher male prevalence in sporadic behavioral variant frontotemporal dementia (bvFTD) has been reported. We hypothesized differences in phenotypes between genetic and sporadic bvFTD females resulting in underdiagnosis of sporadic bvFTD females.METHODSWe included genetic and sporadic bvFTD patients from two multicenter cohorts. We compared behavioral and cognitive symptoms, and gray matter volumes, between genetic and sporadic cases in each sex.RESULTSFemales with sporadic bvFTD showed worse compulsive behavior (p = 0.026) and language impairments (p = 0.024) compared to females with genetic bvFTD (n = 152). Genetic bvFTD females had smaller gray matter volumes than sporadic bvFTD females, particularly in the parietal lobe.DISCUSSIONFemales with sporadic bvFTD exhibit a distinct clinical phenotype compared to females with genetic bvFTD. This difference may explain the discrepancy in prevalence between genetic and sporadic cases, as some females without genetic mutations may be misdiagnosed due to atypical bvFTD symptom presentation.Highlights Sex ratio is equal in genetic behavioral variant of frontotemporal dementia (bvFTD), whereas more males are present in sporadic bvFTD. Distinct neuropsychiatric phenotypes exist between sporadic and genetic bvFTD in females. Phenotype might explain the sex ratio difference between sporadic and genetic cases.
Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute
Levine, Deborah J. , Castillo, Howard, Arcasoy, Selim M. , Benvenuto, Luke , Cevasco, Marisa , Demarest, Caitlin T. , Dewachter, Céline , Erasmus, Michiel E. , Glanville, Allan R. , Granton, John , Khangoora, Vikramjit, Krishnan, Sheila , Miltiades, Andrea , Murphy, Edward L. , Robbins, Ivan M. , Rahaghi, Franck , Saddoughi, Sahar A. , Vachiéry, Jean-Luc, Whitford, Helen, Girgis, Reda E. , Kolaitis, Nicholas A , Arcasoy, Selim M , Mercier, Olaf , Montani, David , Robbins, Ivan , Barnes, Hayley , Bacchetta, Matthew , Rosenzweig, Erika B. , Keshavjee, Shaf , Saddoughi, Sahar A. , Savale, Laurent , Simon, Marc A. , Vachiéry, Jean‐Luc , Ventetuolo, Corey E.

Mayo Clinic

Pulmonary Circulation | April 24, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/pul2.70088 | PMID 40276473 Get It

ABSTRACTLung transplantation is indicated for selected patients with advanced pulmonary arterial hypertension (PAH). We used a modified Delphi process to develop recommendations on care of patients with PAH undergoing lung transplantation. This Delphi panel was recruited from the Pulmonary Vascular Research Institute's Innovative Drug Discovery Initiative ‐ Lung Transplantation Workstream, consisting of clinical and research experts in PAH and lung transplantation. In this process, 29 panelists were given open‐ended questions, querying topics related to lung transplantation in PAH. A steering group converted the responses into discrete statements. Panelists then rated agreement using a Likert scale in two further survey rounds: −5 (strongly disagree) to 5 (strongly agree). Consensus was defined as mean ≥ 2.5 or ≤ −2.5, with a standard deviation not crossing zero. Consensus was reached on 141 of 223 statements. Notable areas of consensus were for early discussions about transplantation, and agreement with previously published referral and listing criteria. There was agreement that lung transplantation could be offered in sick candidates, including those with concurrent renal or hepatic insufficiency. Bilateral lung transplantation was considered the procedure of choice for most patients, with rare indications for heart‐lung transplantation. Consensus on bridging strategies included use of veno‐arterial extracorporeal membrane oxygenation and preemptive awake cannulation in those with severe right ventricular dysfunction. Consensus was also achieved on intraoperative use of invasive hemodynamic monitoring, and prolonged postoperative circulatory support guided by hemodynamic response and echocardiography. Patients with PAH undergoing transplantation require specialized management, which differs somewhat from other candidates.